ZIVO — Zivo Bioscience Income Statement
0.000.00%
Last trade - 00:00
- $40.39m
- $40.92m
- $0.03m
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.02 | 0 | 0 | 0.028 |
Cost of Revenue | |||||
Gross Profit | — | — | — | — | 0.012 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 8.35 | 8.58 | 8.52 | 8.73 | 7.29 |
Operating Profit | -8.35 | -8.56 | -8.52 | -8.73 | -7.26 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -11.5 | -9.11 | -8.76 | -8.75 | -7.78 |
Net Income After Taxes | -11.5 | -9.11 | -8.76 | -8.75 | -7.78 |
Net Income Before Extraordinary Items | |||||
Net Income | -11.5 | -9.11 | -8.76 | -8.75 | -7.78 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -11.5 | -9.11 | -8.76 | -8.75 | -7.78 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -20 | -10.8 | -6.98 | -5.57 | -4.6 |